{"id":547439,"date":"2025-10-15T00:00:00","date_gmt":"2025-10-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0005-2025-biopharma-metabolic-dysfunction-associated-steatohepatitis-unmet-need-unmet-need-metabolic-dysfunction\/"},"modified":"2026-04-23T11:16:28","modified_gmt":"2026-04-23T11:16:28","slug":"unnemd0005-2025-biopharma-metabolic-dysfunction-associated-steatohepatitis-unmet-need-unmet-need-metabolic-dysfunction","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0005-2025-biopharma-metabolic-dysfunction-associated-steatohepatitis-unmet-need-unmet-need-metabolic-dysfunction\/","title":{"rendered":"Metabolic Dysfunction-Associated Steatohepatitis &#8211; Unmet Need &#8211; Unmet Need &#8211; Metabolic Dysfunction-Associated Steatohepatitis (US\/EU)"},"content":{"rendered":"<p>Metabolic dysfunction-associated steatohepatitis (<abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr>), previously known as nonalcoholic steatohepatitis (<abbr title=\"nonalcoholic steatohepatitis\">NASH<\/abbr>), has the potential to be a large and lucrative therapy market owing to the disease\u2019s prevalence and the limited number of approved agents. Patients with <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr> are at risk of liver fibrosis, cardiovascular disease, and cancer. In 2024, the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approved the first-ever drug for <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr>: resmetirom (Rezdiffra). Guidelines recommend the use of available therapies for the management of comorbidities associated with <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr>. Consequently, there is a pressing need for new, effective <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr>-specific drug treatments. In this report, hepatologists and gastroenterologists reveal which attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr> treatments. Using the Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) Simulator, we can establish physicians\u2019 preferences for emerging drugs and assess if these drugs can capitalize on this untapped space.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do hepatologists and gastroenterologists rate current <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr> treatment options such as resmetirom, pioglitazone, and <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr title=\"receptor agonist\">RA<\/abbr> products?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>What trade-offs across different clinical attributes and price are needed from new <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr> drugs to be preferred over current treatment options?<\/li>\n<li>What are the areas of greatest unmet need and opportunity in <abbr title=\"metabolic dysfunction-associated steatohepatitis\">MASH<\/abbr>?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> Survey of 60 U.S. and 32 European medical oncologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Resmetirom, <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr title=\"receptor agonist\">RA<\/abbr> products, vitamin E, pioglitazone<\/p>\n<p><strong>Key feature:<\/strong> Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-547439","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547439\/revisions"}],"predecessor-version":[{"id":547731,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547439\/revisions\/547731"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=547439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}